Q4 FY2025 · ended Dec 31, 2025 · Revenue $11.04M · Filed Mar 23, 2026
Pyxis Oncology, Inc. (PYXS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.3 million. As of Sep 30, 2026 it held $55.6 million in cash and investments and $17.4 million in total debt.
Revenue
$11.04M
Net income
$-19.98M
+9.2% vs year-ago quarter
Operating cash flow
$-16.29M
-22.7% vs year-ago quarter
Free cash flow
$-16.29M
-20.7% vs year-ago quarter
EPS
$-0.24
+31.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
119.61M
+92.1% vs year-ago quarter
Net cash
$38.17M
Q3 FY2026
Operating margin
-165.7%
Q4 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PYXS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782223
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $11.0M | $0 |
| Operating income | -$20.5M | -$26.0M | -$24.4M | -$18.3M | -$23.5M |
| Net income | -$20.0M | -$25.3M | -$23.3M | -$18.1M | -$22.0M |
| Diluted EPS | -$0.24 | -$0.40 | -$0.37 | -$0.29 | -$0.35 |
| Operating cash flow | -$16.3M | -$18.2M | -$26.0M | -$10.4M | -$13.3M |
| Free cash flow | -$16.3M | — | — | -$10.4M | -$13.5M |
| Total assets | $76.8M | $54.9M | $64.3M | $91.5M | $105.6M |
| Total liabilities | $35.5M | $43.5M | $33.0M | $38.1M | $36.8M |
| Stockholders' equity | $41.3M | $11.4M | $31.3M | $53.4M | $68.8M |
| Cash and investments | $55.6M | $33.0M | $41.0M | $66.9M | $76.3M |
| Total debt | $17.4M | $17.8M | $18.3M | $18.7M | $19.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 8, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 356 Pyxis Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.